The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.

• Published in: Journal of Viral Hepatitis
• Main Authors: Sibley, A, Han, K H, Abourached, A, Lesmana, L A, Makara, M, Jafri, W, Salupere, R, Assiri, A M, Goldis, A, Abaalkhail, F, Abbas, Z, Abdou, A, Al Braiki, F, Al Hosani, F, Al Jaberi, K, Al Khatry, M, Al Mulla, M A, Al Quraishi, H, Al Rifai, A, Al Serkal, Y, Alam, A, Alavian, S M, Alashgar, H I, Alawadhi, S, Al-Dabal, L, Aldins, P, Alfaleh, F Z, Alghamdi, A S, Al-Hakeem, R, Aljumah, A A, Almessabi, A, Alqutub, A N, Alswat, K A, Altraif, I, Alzaabi, M, Andrea, N, Babatin, M A, Baqir, A, Barakat, M T, Bergmann, O M, Bizri, A R, Blach, S, Chaudhry, A, Choi, M S, Diab, T, Djauzi, S, El Hassan, E S, El Khoury, S, Estes, C, Fakhry, S
• Other Authors: 1 Ctr Dis Anal, Louisville, CO 80026 USA 2 Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea 3 Minist Publ Hlth, Natl Hepatitis Program, Beirut, Lebanon 4 Univ Indonesia, Dr Cipto Mangunkusumo Hosp, Fac Med, Div Hepatobiliary,Dept Internal Med, Jakarta, Indonesia 5 Medistra Hosp, Digest Dis & GI Oncol Ctr, Jakarta, Indonesia 6 St Laszlo Hosp, Cent Outpatient Clin, Budapest, Hungary 7 Aga Khan Univ, Karachi, Pakistan 8 Univ Tartu, Tartu Univ Hosp, EE-50090 Tartu, Estonia 9 Minist Hlth, Dept Prevent Med, Riyadh, Saudi Arabia 10 Univ Med Victor Babes, Gastroenterol Clin, Timisoara, Romania 11 Alfaisal Univ, King Faisal Specialist Hosp & Res Ctr, Dept Liver & Small Bowel Transplantat, Riyadh, Saudi Arabia 12 Ziauddin Univ, Karachi, Pakistan 13 Rashid Hosp, Dubai Hlth Author, Dubai, U Arab Emirates 14 Abu Dhabi Hlth Serv Co, Abu Dhabi, U Arab Emirates 15 Hlth Author Abu Dhabi, Communicable Dis Dept, Abu Dhabi, U Arab Emirates 16 Hlth Author Abu Dhabi, Hlth Regulat Div, Abu Dhabi, U Arab Emirates 17 Ras Al Khaimah Hosp, Ras Al Khaymah, U Arab Emirates 18 Dubai Hlth Author, Dubai, U Arab Emirates 19 Mafraq Hosp, Abu Dhabi, U Arab Emirates 20 Minist Hlth, Hosp Sect, Abu Dhabi, U Arab Emirates 21 Shaikh Zayed Hosp, Lahore, Pakistan 22 Baqiyatallah Univ Med Sci, Baqiyatallah Res Ctr Gastroenterol & Liver Dis, Tehran, Iran 23 Middle East Liver Dis Ctr, Tehran, Iran 24 King Faisal Specialist Hosp & Res Ctr, Dept Med, Riyadh 11211, Saudi Arabia 25 Rashid Hosp, Dubai Hlth Author, Dept Pulm Med, Dubai, U Arab Emirates 26 Pauls Stradins Clin Univ Hosp, Infect Control Dept, Riga, Latvia 27 King Saud Univ, Liver Dis Res Ctr, Riyadh, Saudi Arabia 28 King Fahad Hosp, Dept Med Specialties, Gastroenterol & Hepatol Unit, Riyadh, Saudi Arabia 29 King Abdul Aziz Med City, Riyadh, Saudi Arabia 30 King Saud bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia 31 King Saud Univ, Coll Med, Dept Med, Liver Dis Res Ctr, Riyadh 11461, Saudi Arabia 32 Zayed Mil Hosp, Abu Dhabi, U Arab Emirates 33 Daman Natl Hlth Insurance Co, Abu Dhabi, U Arab Emirates 34 Seyal Med Ctr, Multan, Pakistan 35 Hlth Author Abu Dhabi, Abu Dhabi, U Arab Emirates 36 Landspitali, Div Gastroenterol & Hepatol, Reykjavik, Iceland 37 Amer Univ Beirut, Med Ctr, Fac Med, Div Infect Dis, Beirut, Lebanon 38 Siddiq Sadiq Hosp, Gujranwala Liver Fdn, Gujranwala, Pakistan 39 Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul, South Korea 40 Al Ain Hosp, Al Ain, U Arab Emirates 41 Univ Balamand, St George Hosp, Dept Gastroenterol, Beirut, Lebanon 42 Abu Dhabi Police, Abu Dhabi, U Arab Emirates 43 Khyber Med Univ, Postgrad Med Inst, Peshawar, Pakistan 44 Govt Lady Reading Hosp, Peshawar, Pakistan 45 Landspitali, Reykjavik, Iceland 46 Lady Reading Hosp, Dept Gastroenterol & Hepatol, Peshawar, Pakistan 47 Fundeni Clin Inst, Ctr Gastroenterol & Hepatol, Bucharest, Romania 48 Landspitali, Fac Med, Sch Hlth Sci, Reykjavik, Iceland 49 Univ Med Ctr, Clin Infect Dis & Febrile Illnesses, Ljubljana, Slovenia 50 Univ New S Wales, Kirby Inst, Sydney, NSW, Australia 51 La Trobe Univ, Australian Res Ctr Sex Hlth & Soc, Melbourne, Vic, Australia 52 King Faisal Specialist Hosp & Res Ctr, Liver Transplantat, Riyadh 11211, Saudi Arabia 53 Hepatol Ctr Buda, Budapest, Hungary 54 Somogy Cty Kaposi Mor Teaching Hosp, Dept Gastroenterol, Kaposvar, Hungary 55 Univ Pecs, Dept Med 1, Pecs, Hungary 56 Lebanese Amer Univ, Med Ctr, Rizk Hosp, Beirut, Lebanon 57 Infectol Ctr Latvia, Dept Hepatol, Riga, Latvia 58 Riga Stradins Univ, Dept Infectol & Dermatol, Riga, Latvia 59 Iceland Canc Registry, Reykjavik, Iceland 60 Landspitali, Fac Med, Reykjavik, Iceland 61 Landspitali, Div Infect Dis, Reykjavik, Iceland 62 Soon Chun Hyang Univ, Bucheon Hosp, Dept Internal Med, Bucheon, South Korea 63 Cleveland Clin Abu Dhabi, Inst Digest Dis, Abu Dhabi, U Arab Emirates 64 Vilnius State Univ, Fac Med, Ctr Hepatol Gastroenterol & Dietet, Vilnius, Lithuania 65 Vilnius Gediminas Tech Univ, Dept Biomech, Vilnius, Lithuania 66 Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol, Seoul, South Korea 67 Landspitali, Dept Virol, Reykjavik, Iceland 68 Univ Tehran Med Sci, Digest Dis Res Inst, Liver & Pancreatobiliary Dis Res Ctr, Tehran, Iran 69 AIMS, Hyderabad, Sindh, Pakistan 70 Lebanese Amer Univ, Med Ctr, Rizk Hosp, Div Infect Dis, Beirut, Lebanon 71 Lebanese Amer Univ, Med Ctr, Rizk Hosp, Div Clin Microbiol, Beirut, Lebanon 72 Amer Univ Beirut, Med Ctr, Div Gastroenterol, Beirut, Lebanon 73 Eijkman Inst Mol Biol, Jakarta, Indonesia 74 Univ Sydney, Dept Hepatitis & Emerging Infect Dis, Sydney, NSW 2006, Australia 75 Fatima Mem Hosp, Coll Med & Dent, Dept Gastroenterol, Lahore, Pakistan 76 Minist Hlth, Directorate Direct Transmitted Dis Control Dis Co, Subdirectorate Gastrointestinal Infect Diarrheal, Jakarta, Indonesia 77 Minist Hlth, Directorate Direct Transmitted Dis Control Dis Co, Jakarta, Indonesia 78 Pakistan Med Res Council, Islamabad, Pakistan 79 Khawar Clin, Sahiwal, Pakistan 80 Mil Hosp, Dept Gastroenterol, Rawalpindi, Pakistan 81 St Joseph Univ, Sch Med Sci, Dept Gastroenterol & Hepatol, Beirut, Lebanon 82 Jinnah Mem Hosp, Rawalpindi, Pakistan 83 Yusra Med Coll, Rawalpindi, Pakistan 84 Allama Iqbal Med Coll, Lahore, Pakistan 85 Directorate Hlth Iceland, Ctr Hlth Secur & Communicable Dis Control, Reykjavik, Iceland 86 Klin Hati Prof Ali Sulaiman, Jakarta, Indonesia 87 Enaya Insurance Co, Hlth Funding Dept, Abu Dhabi, U Arab Emirates 88 Tawam Hosp, Dept Med, Al Ain, U Arab Emirates 89 Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Epidemiol Infect Dis Control & Prevent, Hiroshima, Japan 90 Tawam Hosp, Dept Pharm, Al Ain, U Arab Emirates 91 Lahore Gen Hosp, Postgrad Med Inst, Lahore, Pakistan 92 Doctors Hosp & Med Ctr, Lahore, Pakistan 93 Pakistan Soc Gastroenterol, Karachi, Pakistan 94 Rawalpindi Med Coll, Dept Med, Rawalpindi, Pakistan 95 Holy Family Hosp, Dept Med, Rawalpindi, Pakistan 96 Univ Indonesia, Fac Med, Dept Internal Med, Jakarta, Indonesia 97 Shaukat Khanum Mem Canc Hosp & Res Ctr, Lahore, Pakistan 98 Dow Med Coll, Karachi, Pakistan
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley-Blackwell 2015
• Subjects: Lifrarbólga C; Hepatitis C/diagnosis; Hepatitis C/drug therapy; Hepatitis C/epidemiology; Hepatitis C/mortality; Hepacivirus; Cost of Illness; Prevalence; Iceland
• Online Access: http://hdl.handle.net/2336/592863; https://doi.org/10.1111/jvh.12476

To access publisher's full text version of this article click on the hyperlink at the bottom of the page The total number, morbidity and mortality attributed to viraemic hepatitis C virus (HCV) infections change over time making it difficult to compare reported estimates from different years. Models were developed for 15 countries to quantify and characterize the viraemic population and forecast the changes in the infected population and the corresponding disease burden from 2014 to 2030. With the exception of Iceland, Iran, Latvia and Pakistan, the total number of viraemic HCV infections is expected to decline from 2014 to 2030, but the associated morbidity and mortality are expected to increase in all countries except for Japan and South Korea. In the latter two countries, mortality due to an ageing population will drive down prevalence, morbidity and mortality. On the other hand, both countries have already experienced a rapid increase in HCV-related mortality and morbidity. HCV-related morbidity and mortality are projected to increase between 2014 and 2030 in all other countries as result of an ageing HCV-infected population. Thus, although the total number of HCV countries is expected to decline in most countries studied, the associated disease burden is expected to increase. The current treatment paradigm is inadequate if large reductions in HCV-related morbidity and mortality are to be achieved. Gilead Sciences Center for Disease Analysis